Company Updates
Events

Small Pharma is pleased to announce its attendance at the 11th Annual LifeSci Partners Annual Corporate Access Event. 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022) Small Pharma is participating in the 11th Annual LifeSci Partners Corporate Access Event and an expert panel discussion, which will be hosted virtually.  The panel discussion titled […]

Events

Small Pharma is participating in the H.C. Wainwright Bioconnect Conference which is being held Monday, January 10 to Wednesday, January 13, 2022. H.C. Wainwright Bioconnect Conference (January 10-13, 2022) Small Pharma will also participate in a fireside chat at the H.C. Wainwright Bioconnect Conference, which will be held virtually. The fireside chat will be available […]

Events

Small Pharma is participating in the H.C. Wainwright 2nd Annual Psychedelics Virtual Conference which is being held virtually on Monday, December 6, 2021.  A webcast presentation hosted by Peter Rands, Small Pharma’s Chief Executive Officer, will be available to view on demand beginning on December 6, 2021 at 7:00 a.m ET.  Webcast Information: Presenter: Peter […]

Press Releases

LONDON, Nov. 15, 2021  -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of major d

Press Releases

LONDON, Nov. 15, 2021  -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, today confirms, following positive discussions with the U.S. Food and Drug Administration (the “FDA”), that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of major d

Press Releases

LONDON, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a neuropharmaceutical company focused on psychedelic-assisted therapies, is pleased to announce its attendance at the LSX Inv€$tival ShowcaseTM conference and the Jefferies London Healthcare Conference during the month of November.

Events

Small Pharma is participating in the LSX Inv€$tival ShowcaseTM conference. Peter Rands, Chief Executive Officer, and Dr. Carol Routledge, Chief Medical and Scientific Officer, are presenting a webcast on the Company’s progress in the development of N,N-dimethyltryptamine (“DMT”) assisted therapy for the treatment of Major Depressive Disorder (“MDD”), which is available on-demand via the conference […]

Press Releases

LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").

Press Releases

LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").

Press Releases

LONDON, Sept. 21, 2021 /PRNewswire/ -- Small Pharma Inc. (TSXV: DMT) (the "Company" or "Small Pharma"), a neuropharmaceutical company focused on psychedelic-assisted therapies, today announced both the successful completion of the Phase I part of the combined Phase I/IIa clinical trial and the initiation of the Phase IIa part in combination with psychotherapy of its lead candidate, SPL026, for the treatment of Major Depressive Disorder ("MDD").

About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: